-

12:23:03 PM

XAIR Stock News

XAIR - Beyond Air Inc

10/02/23 4:05 PM

Nasdaq : XAIR

conferences

Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients

RHEA-AI

neutral

09/27/23 9:00 AM

Nasdaq : XAIR

conferencesclinical trial

Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting

Beyond Cancer, Ltd. (the “Company”), an affiliate of Beyond Air, Inc. (NASDAQ:

RHEA-AI

neutral

09/18/23 4:05 PM

Nasdaq : XAIR

clinical trial

Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder

New data demonstrates a therapeutic effect for at least 10 days after a single subcutaneously (SC) injection of an extended-release selective neuronal nitric oxide synthase (nNOS) inhibitor The slow-release formulation led to reversal of behavioral phenotypes and the nitrosative stress of the

RHEA-AI

neutral

09/07/23 7:30 AM

Nasdaq : XAIR

Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region

Beyond Air, Inc. (NASDAQ: XAIR)

RHEA-AI

very positive

09/06/23 7:00 AM

Nasdaq : XAIR

conferences

Beyond Air® To Participate in the 2023 Cantor Global Healthcare Conference

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients

RHEA-AI

neutral

08/10/23 4:05 PM

Nasdaq : XAIR

earnings

Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024

Reported commercial sales for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Currently have in excess of $1 million in annual commercial LungFit PH contracts Secured up to $40 million in debt

RHEA-AI

neutral

08/07/23 4:05 PM

Nasdaq : XAIR

clinical trial

Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)

Data to be presented at the 2023 International Society of Neurochemistry (ISN) and the European Society of Neurochemistry (ESN) meeting in Portugal Data provides further evidence that selective neuronal nitric oxide synthase (nNOS) inhibitors can play a role in the treatment of ASD Poster

RHEA-AI

neutral

08/01/23 4:05 PM

Nasdaq : XAIR

conferences

Beyond Air® To Participate in BTIG’s 2023 Virtual Biotechnology Conference

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients

RHEA-AI

neutral

07/24/23 4:05 PM

Nasdaq : XAIR

earnings

Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and

RHEA-AI

neutral

06/22/23 4:05 PM

Nasdaq : XAIR

earnings

Beyond Air® Reports Financial Results for Fourth Quarter and Fiscal Year-End 2023

Successfully completed phase 1 of U.S. commercial launch, with multiple hospitals contracted, and have initiated phase 2 of launch for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Presented positive preclinical data for ultra-high concentration

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

XAIR Data

IndustryOther Industrial Machinery Manufacturing
Websitehttps://www.beyondair.net/
Security nameBeyond Air Inc
SectorManufacturing
Tags
- Technology Services
- Packaged Software
- Manufacturing
- Other Industrial Machinery Manufacturing
CountryUS

About Beyond Air Inc

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.